Pub Date : 2019-02-23DOI: 10.20473/JSCRTE.V2I2.11895
Adisti Dwijayanti
Brain-Derived Neurotrophic Factor (BDNF) levels were affected by aging. Brain BDNF levels were known to decrease along with advanced age thus correlated with any diseases such as cognitive impairment and Alzheimer. Mesenchymal Stem Cell (MSC) is one of the potential modalities actively investigated against age-related diseases. This study evaluated the effect of human MSC administration to brain BDNF levels in aged rats. Intravenous injection of 10 million per body weight human MSC were given four times in 3 months interval to 22-24 months old female and male Spraque–Dawley rats. As control group, aged rats were injected by normal saline at the same volume and frequencies. Moreover, young 3-6 months rats also examined as negative control. By the end of the experiment, we analyzed three rats from each group. Brain BDNF levels were measured by enzyme-linked immunosorbent assay and normalize to the protein levels. One-way ANOVA and LSD post hoc analysis was performed to compare the differences between groups. BDNF levels in male appeared similar between young, aged, and MSC treated groups. Meanwhile, control aged female groups had significantly lower BDNF levels compared to young (p = 0.019) and MSC-treated aged rats (p = 0.001). There was no difference of BDNF levels between young and MSC-treated aged in female rats (p = 0,068). Both sex had similar BDNF levels (p = 0.249) in control-aged groups. In contrast, female young and MSC-treated aged rats achieved significantly higher BDNF levels (p = 0.009 and p <0.001) compared to the male groups, respectively. These results suggest that human mesenchymal stem cell intravenous injection can increase brain BDNF levels in female aged rats.
{"title":"Brain Derived Neurotrophic Factor Levels in Aged Rats Post-Systemic Human Mesenchymal Stem Cell Administration","authors":"Adisti Dwijayanti","doi":"10.20473/JSCRTE.V2I2.11895","DOIUrl":"https://doi.org/10.20473/JSCRTE.V2I2.11895","url":null,"abstract":"Brain-Derived Neurotrophic Factor (BDNF) levels were affected by aging. Brain BDNF levels were known to decrease along with advanced age thus correlated with any diseases such as cognitive impairment and Alzheimer. Mesenchymal Stem Cell (MSC) is one of the potential modalities actively investigated against age-related diseases. This study evaluated the effect of human MSC administration to brain BDNF levels in aged rats. Intravenous injection of 10 million per body weight human MSC were given four times in 3 months interval to 22-24 months old female and male Spraque–Dawley rats. As control group, aged rats were injected by normal saline at the same volume and frequencies. Moreover, young 3-6 months rats also examined as negative control. By the end of the experiment, we analyzed three rats from each group. Brain BDNF levels were measured by enzyme-linked immunosorbent assay and normalize to the protein levels. One-way ANOVA and LSD post hoc analysis was performed to compare the differences between groups. BDNF levels in male appeared similar between young, aged, and MSC treated groups. Meanwhile, control aged female groups had significantly lower BDNF levels compared to young (p = 0.019) and MSC-treated aged rats (p = 0.001). There was no difference of BDNF levels between young and MSC-treated aged in female rats (p = 0,068). Both sex had similar BDNF levels (p = 0.249) in control-aged groups. In contrast, female young and MSC-treated aged rats achieved significantly higher BDNF levels (p = 0.009 and p <0.001) compared to the male groups, respectively. These results suggest that human mesenchymal stem cell intravenous injection can increase brain BDNF levels in female aged rats.","PeriodicalId":17049,"journal":{"name":"Journal of Stem Cell Research and Tissue Engineering","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81647759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-18DOI: 10.20473/JSCRTE.V2I1.9259
petrasama petrasama
ACL reconstruction measures aim to obtain stable knees, and reduce the risk of further injury to the meniscus and joint surfaces. Acceleration of the integration process between the tendon graft and the bone tunnel will improve the final result of ACL reconstruction. The purpose of this study was to investigate the collagen composition of the bone tunnel graft model of anterior cruciate ligament reconstruction with intravenous allogenic bone marrow mesenchymal stem cells and vascular endothelial growth factor in experimental animals. The design of this study was Post-test only Control Group Design using 20 rabbits divided into treatment group and control group. Collagen immunohistochemical evaluation was performed at weeks 3 and 6. Evaluation at week 3 obtained the area of collagen type-1 in the higher treatment group at treatment (p <0.001). In the 6th week evaluation, it was found that the area of collagen type-1 in the treatment group was higher (p <0.05). Type-1 collagen at week 6 did not differ significantly with week 3 (p> 0.05). Provision of allogenic bone marrow mesenchymal stem cells and intratonal vascular endothelial growth factor in ACL reconstruction enhanced the formation of collagen type-1 which is the acceleration of incorporation of the graft tendon process with bone tunnel.Keywords : Anterior Cruciate Ligament, allogenic bone marrow mesenchymal stemcells, vascular endothelial growth factor, graft and collagen.
{"title":"COLLAGEN ANALYSIS OF GRAFT IN BONE TUNNEL MODEL ANTERIOR CRUCIATE LIGAMENT (ACL) RECONSTRUCTION WITH INTRATUNNEL ALLOGENIC BONE MARROW MESENCHYMAL STEM CELLS (MSCs) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)","authors":"petrasama petrasama","doi":"10.20473/JSCRTE.V2I1.9259","DOIUrl":"https://doi.org/10.20473/JSCRTE.V2I1.9259","url":null,"abstract":"ACL reconstruction measures aim to obtain stable knees, and reduce the risk of further injury to the meniscus and joint surfaces. Acceleration of the integration process between the tendon graft and the bone tunnel will improve the final result of ACL reconstruction. The purpose of this study was to investigate the collagen composition of the bone tunnel graft model of anterior cruciate ligament reconstruction with intravenous allogenic bone marrow mesenchymal stem cells and vascular endothelial growth factor in experimental animals. The design of this study was Post-test only Control Group Design using 20 rabbits divided into treatment group and control group. Collagen immunohistochemical evaluation was performed at weeks 3 and 6. Evaluation at week 3 obtained the area of collagen type-1 in the higher treatment group at treatment (p <0.001). In the 6th week evaluation, it was found that the area of collagen type-1 in the treatment group was higher (p <0.05). Type-1 collagen at week 6 did not differ significantly with week 3 (p> 0.05). Provision of allogenic bone marrow mesenchymal stem cells and intratonal vascular endothelial growth factor in ACL reconstruction enhanced the formation of collagen type-1 which is the acceleration of incorporation of the graft tendon process with bone tunnel.Keywords : Anterior Cruciate Ligament, allogenic bone marrow mesenchymal stemcells, vascular endothelial growth factor, graft and collagen.","PeriodicalId":17049,"journal":{"name":"Journal of Stem Cell Research and Tissue Engineering","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88666338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-18DOI: 10.20473/jscrte.v2i1.9258
A. Abirama
The success of the Anterior Cruciate Ligament (ACL) reconstruction using a tendon graft is determined by integration in the bone tendon-graft interface on the bone tunnel. The use of stem cells and growth factors proved to accelerate the healing of the bone tendon-graft interface. The aim of this study was to inveestigate the difference of histology picture in the tendon-bone tunnel model after ACL reconstruction with intratunnel intravenous allogenic bone marrow mesenchymalstemcells (BM-MSCs) and intratunnel vascular endothelial growth factor (VEGF). This research used Post-Test Only Control Group design with 20 rabbits divided into treatment group and control group. Each group performed histologic image evaluation (thickness of collagen fiber or sharpey fiber) at week 3 and 6. Evaluation of histology overview at week 3 and week 6 showed a significantly thicker thickness of collagen fiber or sharpey fiber in treatment group compared with control group (p <0.05). Intravenous administration of BM-SCs and VEGF after ACL reconstruction can speed healing of the bone tunnel significantly from week 3 and 6. The study by Faridyan et al has concluded that intravenous BM-SCs + VEGF increased ultimate tension strength in the bone-tendon interface significantly. In this study, intravenous administration of BM-SCs and VEGF gave histologic images showing acceleration of bone tunnel healing.Keywords:Anterior cruciate ligament reconstruction, allogenic bone marrow mesenchymal stem cells, vascular endothelial growth factor, graft tunnel healing, and Sharpey fiber.
{"title":"INTRATUNNEL THE EFFECT OF ADMINISTRATION OF BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCs) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TENDON-BONE TO INTERFACE HISTOLOGICAL GRAFT ANTERIOR CRUCIATE LIGAMENT APPEARANCE AFTER RECONSTRUCTION IN RABBITS","authors":"A. Abirama","doi":"10.20473/jscrte.v2i1.9258","DOIUrl":"https://doi.org/10.20473/jscrte.v2i1.9258","url":null,"abstract":"The success of the Anterior Cruciate Ligament (ACL) reconstruction using a tendon graft is determined by integration in the bone tendon-graft interface on the bone tunnel. The use of stem cells and growth factors proved to accelerate the healing of the bone tendon-graft interface. The aim of this study was to inveestigate the difference of histology picture in the tendon-bone tunnel model after ACL reconstruction with intratunnel intravenous allogenic bone marrow mesenchymalstemcells (BM-MSCs) and intratunnel vascular endothelial growth factor (VEGF). This research used Post-Test Only Control Group design with 20 rabbits divided into treatment group and control group. Each group performed histologic image evaluation (thickness of collagen fiber or sharpey fiber) at week 3 and 6. Evaluation of histology overview at week 3 and week 6 showed a significantly thicker thickness of collagen fiber or sharpey fiber in treatment group compared with control group (p <0.05). Intravenous administration of BM-SCs and VEGF after ACL reconstruction can speed healing of the bone tunnel significantly from week 3 and 6. The study by Faridyan et al has concluded that intravenous BM-SCs + VEGF increased ultimate tension strength in the bone-tendon interface significantly. In this study, intravenous administration of BM-SCs and VEGF gave histologic images showing acceleration of bone tunnel healing.Keywords:Anterior cruciate ligament reconstruction, allogenic bone marrow mesenchymal stem cells, vascular endothelial growth factor, graft tunnel healing, and Sharpey fiber.","PeriodicalId":17049,"journal":{"name":"Journal of Stem Cell Research and Tissue Engineering","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87569565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-18DOI: 10.20473/JSCRTE.V2I1.9260
S. Taufik, D. Utomo
The joint cartilage defectfullthickness is still a problem today because its currenttreatment still has not delivered maximum results. Current treatment uses cartilage enginering using mesenchymal stem cells alone and or combining growth factor. The aim of this study was to investigate the effect of intra-articular injection of Allogenic bone marrow mesenchymal stem cell - Platelet rich plasma (BMSCs-PRP) on regeneration of cartilage defect fullthickness in rabbits. The design of this study was a post-test only control group design using 36 New Zealand white rabbits divided into three groups. Each group were treated with PRP, BMSCs and BMSCs-PRP. Results were evaluated after 10 weeks. In the evaluation, macroscopic images showed the best healing in the BMSCs-PRP group. Histopathologic examination showed that in the MSCs-PRP group, there was a significant increase in the number of chondrocytes (p = 0,000), cartilage area (p = 0,000), as well as the number of Agecoprogenitorexpec- tion cells (p = 0,000) and collagen type 2 (p = 0,000). BMSCs were able to differentiate into condroblasts which then synthesize aggressive and collagen type 2. Platelet rich plasma (PRP) contains growth factor BMP, TGF, FGF and IGF which can accelerate the occurrence of MSCs differentiation. Intra-articular injections Allogenic bone marrow mesenchymal stem cell (BMSCs-PRP) is able to regenerate and cure full-thickness joint cartilage defects through differentiation of MSCs into condroblasts.Keyword: Allogenic, Bone marrow Mesenchymal stem cell, Cartilage, Platelet rich plasma, Full-thickness.
{"title":"THE EFFECT OF INJECTION OF INTRA ARTICULAR ALLOGENIC BONE MARROW MESENCHYMAL STEM CELL-PLATELET CELL RICH PLASMA (BMSCs-PRP) ON FULL-THICKNESS ARTICULAR CARTILAGE DEFFECT REGENERATION IN RABBIT","authors":"S. Taufik, D. Utomo","doi":"10.20473/JSCRTE.V2I1.9260","DOIUrl":"https://doi.org/10.20473/JSCRTE.V2I1.9260","url":null,"abstract":"The joint cartilage defectfullthickness is still a problem today because its currenttreatment still has not delivered maximum results. Current treatment uses cartilage enginering using mesenchymal stem cells alone and or combining growth factor. The aim of this study was to investigate the effect of intra-articular injection of Allogenic bone marrow mesenchymal stem cell - Platelet rich plasma (BMSCs-PRP) on regeneration of cartilage defect fullthickness in rabbits. The design of this study was a post-test only control group design using 36 New Zealand white rabbits divided into three groups. Each group were treated with PRP, BMSCs and BMSCs-PRP. Results were evaluated after 10 weeks. In the evaluation, macroscopic images showed the best healing in the BMSCs-PRP group. Histopathologic examination showed that in the MSCs-PRP group, there was a significant increase in the number of chondrocytes (p = 0,000), cartilage area (p = 0,000), as well as the number of Agecoprogenitorexpec- tion cells (p = 0,000) and collagen type 2 (p = 0,000). BMSCs were able to differentiate into condroblasts which then synthesize aggressive and collagen type 2. Platelet rich plasma (PRP) contains growth factor BMP, TGF, FGF and IGF which can accelerate the occurrence of MSCs differentiation. Intra-articular injections Allogenic bone marrow mesenchymal stem cell (BMSCs-PRP) is able to regenerate and cure full-thickness joint cartilage defects through differentiation of MSCs into condroblasts.Keyword: Allogenic, Bone marrow Mesenchymal stem cell, Cartilage, Platelet rich plasma, Full-thickness.","PeriodicalId":17049,"journal":{"name":"Journal of Stem Cell Research and Tissue Engineering","volume":"297 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72896103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-18DOI: 10.20473/JSCRTE.V2I1.9267
Nugroho Setyowardoyo
The state of low oxygen levels known as hypoxia in humans is considered a dangerous condition is apparently a normal physiological condition and required by the stem cells as they are in the body. Mesencyimal Stem Cells (MSCs) require physiologically optimal conditions of low O2 tension of 1-3% in the bone marrow. The purpose of this study was to reveal the difference between in vitro culture of MSC in normoxia condition (20% O 2 concentration) with hypoxia condition (1% O2 content) especially in terms of viability, pluripotent properties, and MSC proliferation ability of the culture it produces. This research is an explorative laboratory research invitro on Bone Marrow Mesenchymal Stem Cells (BMSCs) culture using hypoxia condition. The study design used Randomized Control Group Post-Test Only Design. This research was conducted for 2 months. There was a significant difference in mean slow proliferation based on the number of Least-like CFU-Cs between the control group, treatment group 1 and treatment group 2, the mean percentage of the number of cells expressing the OCT4 coding gene on immunofluorosense examination between the control group, 1 and the treatment group 2 and the mean percentage of cell numbers expressing the OCT4 coding gene on the immunofluorosense examination between the control group, the treatment group 1 and the treatment group 2 showing p <0.01. There was a significant difference of percentage of non-absorbing color cell number of trypsin blue (viable cells) between control group, treatment group 1, and treatment group 2 showing p value <0.05. This suggests that the precondition of culture with normoxia provides an opportunity for cells to adapt and proliferate before being conditioned in hypoxic cultures. Cultures with hypoxic conditions and preconditions of normoxia are the best culture conditions because they produce cells that are capable of maintaining pluripotency properties while still having better proliferation and viability capability compared with direct hypoxia conditions.Keywords: Hypoxia, normoxia, bone marrow, mesenchymal stem cells.
{"title":"INFLUENCE OF LOW OXYGEN CONDITION OF BONE MARROW MESENCHYMAL STEM CELL","authors":"Nugroho Setyowardoyo","doi":"10.20473/JSCRTE.V2I1.9267","DOIUrl":"https://doi.org/10.20473/JSCRTE.V2I1.9267","url":null,"abstract":"The state of low oxygen levels known as hypoxia in humans is considered a dangerous condition is apparently a normal physiological condition and required by the stem cells as they are in the body. Mesencyimal Stem Cells (MSCs) require physiologically optimal conditions of low O2 tension of 1-3% in the bone marrow. The purpose of this study was to reveal the difference between in vitro culture of MSC in normoxia condition (20% O 2 concentration) with hypoxia condition (1% O2 content) especially in terms of viability, pluripotent properties, and MSC proliferation ability of the culture it produces. This research is an explorative laboratory research invitro on Bone Marrow Mesenchymal Stem Cells (BMSCs) culture using hypoxia condition. The study design used Randomized Control Group Post-Test Only Design. This research was conducted for 2 months. There was a significant difference in mean slow proliferation based on the number of Least-like CFU-Cs between the control group, treatment group 1 and treatment group 2, the mean percentage of the number of cells expressing the OCT4 coding gene on immunofluorosense examination between the control group, 1 and the treatment group 2 and the mean percentage of cell numbers expressing the OCT4 coding gene on the immunofluorosense examination between the control group, the treatment group 1 and the treatment group 2 showing p <0.01. There was a significant difference of percentage of non-absorbing color cell number of trypsin blue (viable cells) between control group, treatment group 1, and treatment group 2 showing p value <0.05. This suggests that the precondition of culture with normoxia provides an opportunity for cells to adapt and proliferate before being conditioned in hypoxic cultures. Cultures with hypoxic conditions and preconditions of normoxia are the best culture conditions because they produce cells that are capable of maintaining pluripotency properties while still having better proliferation and viability capability compared with direct hypoxia conditions.Keywords: Hypoxia, normoxia, bone marrow, mesenchymal stem cells.","PeriodicalId":17049,"journal":{"name":"Journal of Stem Cell Research and Tissue Engineering","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81928035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-18DOI: 10.20473/jscrte.v2i1.9262
brian vicky faridyan
Successful anterior cruciate ligament (ACL) reconstruction using tendon graft requires good and rapid integration between the tendon graft and the bone tunnel. The strength of the tendon-bone tunnel graft in the initial phase is very important to facilitate aggressive rehabilitation and as early as possible to support rapid recovery to normal activities. The objective of this study was to determine ultimate tension strength (UTS) on the femoral tendon-bone tunnel graft model after reconstruction of anterior cruciate ligament (ACL) by administering allogenic bone marrow mesenchymal stemcells (BM-MSCs) and vascular endothelial growth factor (VEGF) intratunnel in experimental animals. The design of this research was Post-Test Only Control Group Design using 24 rabbits divided into treatment and control group. Biomechanical evaluation was done at week 3 and 6. Evaluation at week 3 found ultimate tension strength of treatment group significantly higher than control (p <0,05). In the 6th week evaluation, Ultimate tension strength was found that the treatment group significantly higher than the control group (p <0.05). Ultimate tension strength at week 3 did not differ significantly with week 6 (p> 0.05). Intravenous administration of BM-MSCs and VEGF on ACL reconstruction increased ultimate tension strength in graft-bone tunnel significantly since week 3. The study of Ferdiansis et al using BM-MSCs and VEGF intraarticular, only showed a significant increase in ultimate tension strength in graft-bone tunnel since week 6. Comparison of this method indicates acceleration in incorporation of tendon graft with bone tunnel on intratunnel method better thaninvitro intraarticular method.Keywords : Anterior cruciate ligament, allogenic bone marrow mesenchymal stem cells, vascular endothelial growth factor and biomechanic study.
{"title":"BIOMECHANIC STUDY OF GRAFT BONE TUNNEL MODEL IN ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING INTRATUNNEL ALLOGENIC BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCs) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)","authors":"brian vicky faridyan","doi":"10.20473/jscrte.v2i1.9262","DOIUrl":"https://doi.org/10.20473/jscrte.v2i1.9262","url":null,"abstract":"Successful anterior cruciate ligament (ACL) reconstruction using tendon graft requires good and rapid integration between the tendon graft and the bone tunnel. The strength of the tendon-bone tunnel graft in the initial phase is very important to facilitate aggressive rehabilitation and as early as possible to support rapid recovery to normal activities. The objective of this study was to determine ultimate tension strength (UTS) on the femoral tendon-bone tunnel graft model after reconstruction of anterior cruciate ligament (ACL) by administering allogenic bone marrow mesenchymal stemcells (BM-MSCs) and vascular endothelial growth factor (VEGF) intratunnel in experimental animals. The design of this research was Post-Test Only Control Group Design using 24 rabbits divided into treatment and control group. Biomechanical evaluation was done at week 3 and 6. Evaluation at week 3 found ultimate tension strength of treatment group significantly higher than control (p <0,05). In the 6th week evaluation, Ultimate tension strength was found that the treatment group significantly higher than the control group (p <0.05). Ultimate tension strength at week 3 did not differ significantly with week 6 (p> 0.05). Intravenous administration of BM-MSCs and VEGF on ACL reconstruction increased ultimate tension strength in graft-bone tunnel significantly since week 3. The study of Ferdiansis et al using BM-MSCs and VEGF intraarticular, only showed a significant increase in ultimate tension strength in graft-bone tunnel since week 6. Comparison of this method indicates acceleration in incorporation of tendon graft with bone tunnel on intratunnel method better thaninvitro intraarticular method.Keywords : Anterior cruciate ligament, allogenic bone marrow mesenchymal stem cells, vascular endothelial growth factor and biomechanic study.","PeriodicalId":17049,"journal":{"name":"Journal of Stem Cell Research and Tissue Engineering","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76418488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-11-02DOI: 10.4172/2165-7939.1000266
H. Maulida, D. Hikmawati, A. S. Budiatin
World Health Organization (WHO) in 2005 reported that cases of tuberculosis (TB) in the world occur more than 8 million annually and 5-10% were attacked in spine. The most effective treatment of spinal TB is evacuation of infected bone segments and fill with bone graft. It has been synthesized and characterized of injectable bone substitute (IBS) paste based on hydroxyapatite, gelatin and streptomycin. IBS paste synthesized by mixing hydroxyapatite and gelatin 20% w/v with 75:25, 70:30, 65:35 and 60:40 ratio and streptomycin 10 wt%. The mixture was then added with hydroxypropyl methylcellulose (HPMC) 4% w/v as suspending agent. In vitro characterization performed include acidity (pH), injectability test, setting time, cytotoxicity (MTT assay) and microbacterium test. Acidity test results indicate a fourth variation of the samples had pH values approaching normal body pH (7,3 to 7,6) and is able to maintain stability when measured in 7 days. Injectability test results indicate IBS paste is injectable with the highest percentage of the injectability value at 97,74% ± 0,19%. IBS paste has been setting within 30 minutes to 1 hour when injected on hydroxyapatite scaffold that resembles the bone cavity and is able to cover the pore scaffold seen from the Scanning Electron Microscope (SEM). Scaffold pore size is smaller from range of 780,8 to 835,4 μm into 225,2 μm. MTT assay results showed that IBS paste is not toxic and experiencing proliferation (viability >100%) that are expected to trigger osteoblast cell growth when applied. Microbacterium test results showed that IBS paste is an antibacterial seen from inhibition zone diameter of Staphylococcus aureus and has a high strength-sensitive antibacterial. Thus, hydroxyapatite, gelatin and streptomycin composites had qualified as injectable bone substitute which applied in cases of spinal tuberculosis.
{"title":"Injectable Bone Substitute Paste Based on Hydroxyapatite, Gelatin and Streptomycin for Spinal Tuberculosis","authors":"H. Maulida, D. Hikmawati, A. S. Budiatin","doi":"10.4172/2165-7939.1000266","DOIUrl":"https://doi.org/10.4172/2165-7939.1000266","url":null,"abstract":"World Health Organization (WHO) in 2005 reported that cases of tuberculosis (TB) in the world occur more than 8 million annually and 5-10% were attacked in spine. The most effective treatment of spinal TB is evacuation of infected bone segments and fill with bone graft. It has been synthesized and characterized of injectable bone substitute (IBS) paste based on hydroxyapatite, gelatin and streptomycin. IBS paste synthesized by mixing hydroxyapatite and gelatin 20% w/v with 75:25, 70:30, 65:35 and 60:40 ratio and streptomycin 10 wt%. The mixture was then added with hydroxypropyl methylcellulose (HPMC) 4% w/v as suspending agent. In vitro characterization performed include acidity (pH), injectability test, setting time, cytotoxicity (MTT assay) and microbacterium test. Acidity test results indicate a fourth variation of the samples had pH values approaching normal body pH (7,3 to 7,6) and is able to maintain stability when measured in 7 days. Injectability test results indicate IBS paste is injectable with the highest percentage of the injectability value at 97,74% ± 0,19%. IBS paste has been setting within 30 minutes to 1 hour when injected on hydroxyapatite scaffold that resembles the bone cavity and is able to cover the pore scaffold seen from the Scanning Electron Microscope (SEM). Scaffold pore size is smaller from range of 780,8 to 835,4 μm into 225,2 μm. MTT assay results showed that IBS paste is not toxic and experiencing proliferation (viability >100%) that are expected to trigger osteoblast cell growth when applied. Microbacterium test results showed that IBS paste is an antibacterial seen from inhibition zone diameter of Staphylococcus aureus and has a high strength-sensitive antibacterial. Thus, hydroxyapatite, gelatin and streptomycin composites had qualified as injectable bone substitute which applied in cases of spinal tuberculosis.","PeriodicalId":17049,"journal":{"name":"Journal of Stem Cell Research and Tissue Engineering","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79288376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：